Here's Why Norwegian Cruise Line (NCLH) is a Strong Growth Stock
Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.
Why This 1 Growth Stock Should Be On Your Watchlist
For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.
Norwegian Cruise Line (NCLH)
Norwegian Cruise Line Holdings Ltd., a Bermuda Limited company, is a leading cruise line operator. It owns and operates three brands — Oceania Cruises, Regent Seven Seas Cruises and Norwegian Cruise Line. The company, founded in 1966, is headquartered in Miami, FL.
NCLH sits at a Zacks Rank #3 (Hold), holds a Growth Style Score of B, and has a VGM Score of A. Earnings and sales are forecasted to increase 12.1% and 6.1% year-over-year, respectively.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.01 to $2.04 per share. NCLH also boasts an average earnings surprise of 29.1%.
Looking at cash flow, Norwegian Cruise Line is expected to report cash flow growth of 71.3% this year; NCLH has generated cash flow growth of 0.8% over the past three to five years.
With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, NCLH should be on investors' short lists.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Norwegian Cruise Line Holdings Ltd. (NCLH) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte, Inc. VCYT delivered second-quarter 2025 adjusted earnings of 44 cents per share, which marked a stupendous improvement of 46.7% from the year-ago period's figure of 30 cents. The bottom line beat the Zacks Consensus Estimate by 41.9%. The company's GAAP loss per share (EPS) was 1 cent compared to the year-ago period's earnings of 7 cents per share. Following the earnings announcement, VCYT's share price gained 15.5% last Thursday. VCYT's Q2 Revenues Revenues increased 13.8% year over year to $130.2 million, which outpaced the Zacks Consensus Estimate by 7.1%. VCYT's Q2 Segmental Details Testing revenues totaled $122.3 million, up 14% year over year. This rise was mainly due to Decipher and Afirma revenue growth of 24% and 5%, respectively. Testing volume improved 18% year over year to 42,441 tests. Product revenues fell 8% year over year to $3.6 million. Biopharmaceutical and other revenues of $4.3 million reflected a 21% increase from the prior-year quarter's figure. Margins The total cost of revenues (product, testing, biopharmaceutical and other) was $37.7 million, up 12.3% year over year. The gross profit rose 14.4% to $92.4 million. The gross margin expanded 38 basis points (bps) to 71%. Selling and marketing expenses rose 4.5% to $25.3 million, while general and administrative expenses increased 1.8% to $32.3 million. R&D expenses totaled $16.3 million, down 1.2% year over year. The adjusted operating margin was 14.2%, which expanded 689 bps year over year. VCYT's Cash, Capital Structure and Solvency Veracyte exited second-quarter 2025 with cash and cash equivalents of $219.5 million compared with $186.1 million at the end of the first quarter. The cumulative net cash provided from operating activities at the end of the reported quarter was $39 million compared with $20.6 million a year ago. VCYT's 2025 Guidance Veracyte raised its full-year 2025 testing revenue guidance. The company expects testing revenues to be in the range of $477-$483 million (up from $470-$480 million), implying 14% to 15% year-over-year growth. Veracyte, Inc. Price, Consensus and EPS Surprise Veracyte, Inc. price-consensus-eps-surprise-chart | Veracyte, Inc. Quote Given the resolution of the French subsidiary proceedings, the company initiated full-year 2025 total revenue guidance of $496-$504 million, implying 11% to 13% year-over-year growth. The Zacks Consensus Estimate for the metric is currently pegged at $501.1 billion. The company raised guidance for adjusted EBITDA as a percentage of revenues. It is anticipated to be approximately 23.5% (up from the previous guidance of 22.5%). Our Take Veracyte reported better-than-expected second-quarter results, with its earnings and revenues surpassing their respective estimates. The company registered robust growth from its market-leading Decipher Prostate and Afirma tests. Meanwhile, the growth in Biopharmaceutical and other revenues was encouraging. Both margin expansion instills optimism among investors. In the second quarter, the company had some notable developments, including the launch of Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor. Zacks Rank and Key Picks Veracyte currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Medpace Holdings MEDP, GeneDx Holdings WGS and Cardinal Health CAH. Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today's Zacks #1 Rank stocks here. MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite's 10.1% growth. GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, which exceeded the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%. WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry's 18.6% growth. Cardinal Health, carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2025 adjusted EPS of $2.35, which exceeded the Zacks Consensus Estimate by 9.3%. Revenues of $54.88 billion missed the Zacks Consensus Estimate by 0.3%. CAH has an estimated long-term earnings growth rate of 10.9% compared with the industry's 9.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Veracyte, Inc. (VCYT) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Should You Buy, Hold, or Sell Archer Aviation Stock Ahead of Q2 Earnings?
Archer Aviation Inc. (ACHR) is slated to report second-quarter 2025 results on Aug. 11, 2025, after market close. The Zacks Consensus Estimate for earnings is pegged at a loss of 19 cents per share, suggesting an improvement from a loss of 24 cents in the prior-year quarter. The bottom-line estimate has improved over the past 60 days. Image Source: Zacks Investment Research Archer Aviation's earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, met once and missed in the other, the average negative surprise being 10.86%. Image Source: Zacks Investment Research Earnings Whispers Our proven model predicts an earnings beat for ACHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Archer Aviation has a Zacks Rank #3 and an Earnings ESP of +2.70%. You can see the complete list of today's Zacks #1 Rank stocks here. Key Factors to Consider Ahead of ACHR's Q2 Earnings Release In June 2025, Archer Aviation announced a strategic partnership with Jetex, a global aviation services provider, to develop infrastructure across Jetex's 40 private terminals in over 30 countries, starting with the UAE. The collaboration builds on Archer's existing infrastructure partnerships, aiming to expand a global vertiport network to support its planned commercial air taxi operations and future international growth. In June, Archer Aviation also signed an agreement with PT. IKN to deploy an initial fleet of Midnight aircraft in Indonesia, making it the third country where it plans to deploy Midnight under its 'Launch Edition' program. Such strategic agreements might have contributed favorably to ACHR's second-quarter performance. With the company continuing to invest in its engineering, manufacturing and commercial activities for the Midnight aircraft, it is likely to have incurred notable expenses for the program's development. This, along with an increase in labor and materials spent due to its planned ramp of manufacturing activity for the Midnight aircraft, is likely to have increased Archer Aviation's operating expenses, thereby weighing on its quarterly earnings performance. However, ACHR's technological advancement over the past few quarters while developing the Midnight jet is likely to have provided it with operational efficiency, aiding its quarterly bottom line. The company's quarterly results are also likely to reflect a strong cash balance account, particularly driven by the proceeds from its equity raise worth $850 million, following the White House's announcement of an Executive Order by President Trump to implement an eVTOL Integration Pilot Program in the United States in June. This, in turn, must have brought its total liquidity position to approximately $2 billion, which should be duly reflected in its second-quarter balance sheet on Aug. 11. Price Performance & Valuation ACHR's shares recently exhibited a downward trend, having lost a notable percentage in the past six months. Specifically, the stock fell 3.9% in the said period, underperforming the Zacks aerospace-defense industry's gain of 19.7%. It also lagged the broader Zacks Aerospace sector's return of 19.9% as well as the S&P 500's rise of 4.4%. Image Source: Zacks Investment Research Other notable stocks from the same industry have, however, gained in the past six months. Shares of Embraer (ERJ) and Boeing (BA) have rallied 37.8% and 25.9%, respectively, over the past year. In terms of valuation, ACHR's trailing price/book (P/B) ratio of 5.32 represents a discount to the industry average of 6.22. Image Source: Zacks Investment Research Investment Thesis ACHR offers promising near-term prospects, but whether its business will be sustainable in the long run remains uncertain. This is because the eVTOL aircraft market is still in its early stages, and ACHR's success depends not only on its ability to design, develop and certify eVTOL aircraft but also on how the demand for these vehicles evolves. Public acceptance of eVTOLs as an alternative to traditional transport methods could face hurdles related to safety, noise and affordability concerns. Without widespread recognition, ACHR's growth potential may be constrained. Additionally, ACHR and other aerospace manufacturers like BA and ERJ are navigating industry challenges, including persistent supply-chain disruptions and a shortage of skilled labor. Such factors could hinder ACHR's ability to complete its projects on time. Moreover, a quick glance at the company's return on equity (ROE) over the past year compared to that of its industry reveals a dismal scenario. ACHR's negative ROE indicates that it is incurring a loss, as evident from its recent quarterly results. Image Source: Zacks Investment Research Should You Buy ACHR Before Aug. 11? To conclude, ACHR is less likely to disappoint with its second-quarter results, considering its favorable Zacks Rank, positive Earnings ESP as well as improvement in its bottom-line estimate over the past 60 days. However, investors interested in this stock may consider staying on the sidelines before Monday, taking into account its poor ROE, dismal performance at the bourses as well as industry challenges. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Embraer-Empresa Brasileira de Aeronautica (ERJ) : Free Stock Analysis Report Archer Aviation Inc. (ACHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
VirTra Stock Set to Release Q2 Earnings: What's in Store?
VirTra Inc. (VTSI) is set to release second-quarter 2025 results on Aug. 11, 2025, after market close. The company delivered a trailing four-quarter average earnings surprise of 198.93%. Let's discuss the factors that are likely to be reflected in the upcoming quarterly results. Factors to Note Ahead of VTSI's Q2 Earnings Revenues earned from higher sales of simulators and accessories, along with design & prototyping, can be expected to have boosted VTSI's second-quarter top-line performance. VirTra, Inc. Price and EPS Surprise VirTra, Inc. price-eps-surprise | VirTra, Inc. Quote Also, the successful delivery of the company's V-XR extended reality platform, anticipated in the April-June 2025 quarter, is likely to have contributed favorably to its quarterly revenues. In addition, VirTra's steady use of AI tools to accelerate content development must have enabled it to generate higher volumes of certified training faster than ever before, thereby attracting more customers and bolstering its operational results. However, slower bookings witnessed by the company in recent quarters, due to delays in federal budget disbursements and a more cautious demand environment across the law enforcement and defense sectors, might have hurt both revenues and earnings in the soon-to-be-reported quarter. On the cost side, VTSI can be expected to have witnessed a decrease in cost of sales, caused by greater operational efficiencies, along with reduced operating expenses, thanks to its efforts to lower overhead costs. This, along with solid revenue growth expectations, must have contributed favorably to its second-quarter bottom line. However, ongoing IVAS program development and initial V-XR production runs might have added upfront costs, weighing on its profitability and thereby earnings. Q2 Expectations for VTSI The Zacks Consensus Estimate for revenues is pegged at $6.38 million, indicating a 5.1% rise from the year-ago quarter's reported figure. The Zacks Consensus Estimate for earnings is pegged at 3 cents per share, which indicates a decline of 72.7% from the prior-year reported figure. What the Zacks Model Unveils for VTSI Our proven model does not conclusively predict an earnings beat for VirTra this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. Earnings ESP: VTSI has an Earnings ESP of 0.00%. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Zacks Rank: Currently, VirTra carries a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here. Stocks to Consider Below, we have mentioned players from the same sector that have the right combination of elements to beat on earnings this reporting cycle. Archer Aviation (ACHR) is set to report second-quarter 2025 earnings on Aug. 11, 2025, after market close. It has an Earnings ESP of +2.70% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for ACHR's earnings is pegged at a loss of 19 cents per share, indicating a year-over-year improvement from a loss of 24 cents. Heico Corp. (HEI) is set to report fiscal third-quarter 2025 results soon. It has an Earnings ESP of +1.16% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for HEI's earnings is pegged at $1.12 per share, indicating year-over-year growth of 15.5%. The consensus estimate for sales is pegged at $1.1 billion, indicating year-over-year growth of 12.2%. CAE (CAE) is set to report fiscal first-quarter 2026 results on Aug. 13, 2025, before market open. It has an Earnings ESP of +0.46% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for CAE's earnings is pegged at 15 cents per share. The consensus estimate for sales is pegged at $810.1 million, indicating year-over-year growth of 3.4%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CAE Inc (CAE) : Free Stock Analysis Report Heico Corporation (HEI) : Free Stock Analysis Report VirTra, Inc. (VTSI) : Free Stock Analysis Report Archer Aviation Inc. (ACHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
